ERBB2 and breast cancer: This retrospective study aimed to demonstrate the positive concordance rate between IHC and FISH for HER-2 testing in breast cancer based on the ASCO/CAP 2018 recommendations to confirm positive IHC results for reimbursed anti-HER-2 drugs and decrease the test waiting time to benefit patients in Thailand.